KMC Speciality Hospitals Surges: Q3 PAT Jumps 83% on Strong Revenue Growth

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAbhay Singh|Published at:
KMC Speciality Hospitals Surges: Q3 PAT Jumps 83% on Strong Revenue Growth
Overview

KMC Speciality Hospitals (India) Limited reported a robust Q3 FY26, with revenue from operations soaring 33.73% year-on-year to ₹82.06 Crore. Profit Before Tax (PBT) surged by 83.86% to ₹18.48 Crore, and Profit After Tax (PAT) jumped 82.71% to ₹13.73 Crore. Profit Before Tax margins improved substantially to 22.51% from 16.37% in the prior year's quarter. Sequentially, revenue grew 9.55% and PAT rose 26.63% QoQ, signalling sustained growth momentum.

📉 The Financial Deep Dive

KMC Speciality Hospitals (India) Limited has unveiled a strong financial performance for the third quarter of fiscal year 2026, demonstrating significant year-on-year (YoY) and sequential (QoQ) growth across key metrics.

The Numbers:

  • Revenue from Operations: For the quarter ended December 31, 2025, revenue surged by a remarkable 33.73% YoY to ₹82.06 Crore (₹8,206.03 Lakhs), up from ₹61.36 Crore (₹6,136.41 Lakhs) in Q3 FY25. Sequentially, revenue saw a healthy 9.55% QoQ increase.
  • Profit Before Tax (PBT): PBT witnessed a substantial jump of 83.86% YoY, reaching ₹18.48 Crore (₹1,847.52 Lakhs) compared to ₹10.05 Crore (₹1,004.82 Lakhs) in the previous year.
  • Profit After Tax (PAT): Consequently, PAT grew by an impressive 82.71% YoY to ₹13.73 Crore (₹1,372.78 Lakhs) from ₹7.51 Crore (₹751.38 Lakhs). QoQ PAT growth was equally robust at 26.63%.
  • Margins: The Profit Before Tax margin improved significantly to 22.51% in Q3 FY26 from 16.37% in Q3 FY25, indicating enhanced operational efficiency and profitability.
  • Earnings Per Share (EPS): On an annualised basis, EPS increased to ₹0.84 from ₹0.46 YoY.

The Quality:

The substantial improvement in margins, coupled with strong revenue growth, suggests effective cost management and potential pricing power. A notable point is the significant increase in 'Other Income' to ₹1.24 Crore in Q3 FY26 from ₹0.12 Crore in Q3 FY25, which contributed to the overall profit boost. While this is a positive contributor, investors might seek clarity on the sustainability of such a large increase in other income.

The limited review report from Deloitte Haskins & Sells, Chartered Accountants, provided a clean chit, stating that nothing came to their attention suggesting material misstatements in the accompanying financial statements.

The Grill:

No specific 'grill' or aggressive analyst questioning was mentioned in the provided filing. The report focused on presenting the financial results.

Risks & Outlook:

While the current results are highly encouraging, potential risks for the healthcare sector include evolving regulatory landscapes, increasing competition, and managing operational costs in a dynamic environment. The substantial increase in 'Other Income' warrants closer monitoring in future quarters to ascertain its recurring nature. Investors should watch for management commentary on future capacity expansion, service line growth, and strategies to maintain margin expansion and revenue momentum in the upcoming periods. The company has not provided specific forward-looking guidance in this release.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.